Bicara Therapeutics initiated with a Buy at BTIG

BTIG initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $28 price target Bicara is a clinical stage biotechnology company advancing ficerafusp alfa for head and neck squamous cell carcinoma and other solid tumors, the analyst tells investors in a research note. The firm believes the Phase 1b data for ficera plus pembrolizumab shows clinically differentiated duration of response and survival data compared to the standard of care. It believes the HNSCC market is “capable of supporting multiple players.”